KeyCorp Weighs in on Steris Corp.’s Q4 2017 Earnings (STE)
Steris Corp. (NYSE:STE) – KeyCorp dropped their Q4 2017 EPS estimates for Steris Corp. in a report released on Monday. KeyCorp analyst M. Mishan now anticipates that the brokerage will post earnings per share of $1.15 for the quarter, down from their prior forecast of $1.16.
Separately, Zacks Investment Research raised Steris Corp. from a “sell” rating to a “hold” rating in a report on Thursday, September 29th.
Shares of Steris Corp. (NYSE:STE) traded down 0.40% during trading on Thursday, hitting $71.89. The stock had a trading volume of 332,389 shares. The company has a market cap of $6.19 billion, a PE ratio of 41.29 and a beta of 1.14. The stock’s 50 day moving average is $71.39 and its 200-day moving average is $70.37. Steris Corp. has a 12-month low of $61.38 and a 12-month high of $78.77.
Steris Corp. (NYSE:STE) last issued its earnings results on Tuesday, August 9th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.02. The company earned $638.40 million during the quarter, compared to analysts’ expectations of $639.04 million. Steris Corp. had a return on equity of 10.72% and a net margin of 5.52%. The firm’s quarterly revenue was up 45.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.62 EPS.
A number of institutional investors have recently added to or reduced their stakes in STE. Welch Capital Partners LLC NY bought a new position in Steris Corp. during the first quarter valued at $12,295,000. Palisade Capital Management LLC NJ bought a new position in Steris Corp. during the first quarter valued at $1,839,000. Champlain Investment Partners LLC increased its position in Steris Corp. by 1.1% in the first quarter. Champlain Investment Partners LLC now owns 466,540 shares of the company’s stock valued at $33,148,000 after buying an additional 5,250 shares during the last quarter. JPMorgan Chase & Co. increased its position in Steris Corp. by 43.9% in the first quarter. JPMorgan Chase & Co. now owns 616,502 shares of the company’s stock valued at $43,802,000 after buying an additional 187,935 shares during the last quarter. Finally, Columbia Partners L L C Investment Management bought a new position in Steris Corp. during the first quarter valued at $1,593,000. 91.58% of the stock is owned by institutional investors.
In other Steris Corp. news, CEO Walter M. Rosebrough, Jr. sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $71.08, for a total transaction of $1,066,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Martin Steeves sold 204,778 shares of the firm’s stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $71.19, for a total value of $14,578,145.82. Following the transaction, the director now directly owns 165,434 shares of the company’s stock, valued at approximately $11,777,246.46. The disclosure for this sale can be found here. Company insiders own 2.52% of the company’s stock.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 27th. Shareholders of record on Tuesday, August 30th were given a dividend of $0.28 per share. This is an increase from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend was Friday, August 26th. This represents a $1.12 annualized dividend and a yield of 1.55%. Steris Corp.’s dividend payout ratio (DPR) is presently 68.71%.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Receive News & Stock Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related stocks with our FREE daily email newsletter.